Herpes Simplex Market Insight, Epidemiology & Forecast to 2027 - ResearchAndMarkets.com

DUBLIN--()--The "Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of HSV infections in the United States, EU5, and Japan.

One segment of the HSV infections report encloses the detailed analysis of marketed drugs and late stage pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The current HSV Virus infections market is dependent on antiviral drugs that are not the cure of the disease but relief the symptoms of the disease and in long-term reduces the incidence of relapses if started before exposure to the triggering conditions. Although, antiviral therapies have proven its effectiveness in this market associated complications and need of a cure demands the emergence of novel therapy. Detailed chapter for upcoming therapies Pritelivir, SQX770, BTL TML HSV, GEN 003, VCL-HB01 and M5210B have been covered in the report.

The HSV Infections market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

Companies Mentioned

  • Vical Therapeutics - Medivir
  • Maruho - GlaxoSmithKline
  • AiCuris - BioAlliance
  • Genocea Biosciences - Clinigen
  • Beech Tree Labs - Mylan
  • Squarex - Novartis

Key Topics Covered:

1. Key Insights

2. Herpes Simplex Virus Market Overview at a Glance

3. Disease Background and Overview: Herpes Simplex Virus (HSV)

4. Epidemiology and Patient Population

5. Key Findings

6. Country Wise-Epidemiology of Herpes Simplex Virus (HSV)

7. Treatment Algorithm

8. Unmet needs

9. Marketed drugs

10. Emerging Therapies

11. Key Cross Competition

12. Phase II/III Drugs

13. Herpes Simplex Virus (HSV) Infection: Market Analysis

14. Market Size of HSV by Country

15. Market Drivers of HSV

16. Market Barriers of HSV

17. Appendix

18. Capabilities

19. Disclaimer

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gsw9pq/herpes_simplex?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Sexual and Reproductive Health Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Sexual and Reproductive Health Drugs